Ocugen (FRA:2H51) Days Sales Outstanding

: 0.00 (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

Ocugen's average Accounts Receivable for the three months ended in Dec. 2023 was €0.00 Mil. Ocugen's Revenue for the three months ended in Dec. 2023 was €5.54 Mil. Hence, Ocugen's Days Sales Outstanding for the three months ended in Dec. 2023 was 0.00.

The historical rank and industry rank for Ocugen's Days Sales Outstanding or its related term are showing as below:

FRA:2H51's Days Sales Outstanding is not ranked ^*
in the Biotechnology industry.
Industry Median: 72.335
* Ranked among companies with meaningful Days Sales Outstanding only.

Ocugen's Days Sales Outstanding stayed the same from Dec. 2022 (0.00) to Dec. 2023 (0.00).

Ocugen Days Sales Outstanding Historical Data

The historical data trend for Ocugen's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocugen Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

Ocugen Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Sales Outstanding																-	-	-	-	-

Competitive Comparison

For the Biotechnology subindustry, Ocugen's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ocugen Days Sales Outstanding Distribution

For the Biotechnology industry and Healthcare sector, Ocugen's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Ocugen's Days Sales Outstanding falls into.

Ocugen Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Ocugen's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	5.535	*	365
=	0					/	5.535	*	365
=	0.00

Ocugen's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding (Q: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Sep. 2023 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	5.535	*	365 / 4
=	0					/	5.535	*	365 / 4
=	0.00

Ocugen (FRA:2H51) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Ocugen Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Ocugen's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Ocugen (FRA:2H51) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocugen Inc (FRA:2H51) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

OCGN:USA OCGN:Mexico

Address

11 Great Valley Parkway, Malvern, PA, USA, 19355

Website

https://www.ocugen.com

Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. The breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug one to many and novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy. The company is co-developing Bharat Biotech's COVAXIN vaccine candidate for COVID-19 in the U.S. and Canadian markets.

Ocugen (FRA:2H51) Headlines

No Headlines